Collection

Tumor microenvironment and immunotherapy

Submission status
Closed
This series will focus on basic, translational and clinical research related to the field of tumor microenvironment and immunotherapy. All article types are welcome in this collection.

Articles published in the collection have already gone through the systematic peer review process of the journal.

Editors

  • Bo Zhu Bo Zhu , 

    Bo Zhu

    Dr. Zhu leads a translational group that investigates the tumor microenvironment (TME) with the goal of identifying biomarkers and develo** new strategy for cancer immunotherapy. His laboratory has demonstrated spatial and temporal heterogeneity of the TME-including different population, different organ metastasis and different sites in the same tumor; and TME resha** after target therapy, chemotherapy and immunotherapy. Their work includes the first findings of immunosuppressive extramedullary erythroid progenitor cells (EPCs) induced by tumor which leads to systemic immunosuppression in the cancer patients.

  • Qian Chu Qian Chu  &

    Qian Chu

    Dr. Chu focus on translational research and clinical research in lung cancer, and the tumor microenvironment (TME) is the most important research area. Her group found that the levels of CCL7 were significantly higher in patients who exhibited PR or SD to anti-PD-1 therapies than those who exhibited PD. Their laboratory has demonstrated CCL7 recruits conventional DC1 into the TME to promote T cell expansion. Her group also finds the normalized TME and reinvigorated antitumor immunity contributed to the superior antitumor effect of the combination of Mn2+ and anti-TGF-β/PD-L1.

  • Shengxiang Ren Shengxiang Ren

    Shengxiang Ren

    Dr. Ren’s career in lung cancer research includes immunotherapy, targeted therapies and translational research of lung cancer. Recently, Dr. Ren and his team emphasizes on the characteristics of tumor microenvironment and the mechanism by which tumor cells, immune cell and stomal cells change their cell state and how the changes contribute to the development of tumor niche and metastasis. They attempt to identify the key tumor-derived factors for immunotherapy resistance of lung cancer and investigate potential combination strategy. His research has translated into several clinical trials in lung cancer.

Articles (13 in this collection)